history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine \> 2 mg/dl (\>176.8 μmol/l), or have estimated creatinine clearance \< 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women

history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine \> 2 mg/dl (\>176.8 μmol/l), or have estimated creatinine clearance \< 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women

history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine > 2 mg/dl (>176.8 μmol/l), or have estimated creatinine clearance < 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women

history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine > 2 mg/dl (>176.8 μmol/l), or have estimated creatinine clearance < 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women

history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine > 2 mg/dl (>176.8 μmol/l), or have estimated creatinine clearance < 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply.

history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib. presence of severely impaired renal function defined by serum creatinine > 2 mg/dl (>176.8 μmol/l), or have estimated creatinine clearance < 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. suspected uncontrolled bacterial, fungal, viral, or other infection (besides covid-19). currently intubated or intubated between screening and randomization. in intensive care unit (icu) at time of randomization. intubated or in icu for covid-19 disease prior to screening. patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). unable to ingest tablets at randomization. pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply.